Straumann Dental Implants, The Swiss Gold Standard

Overview, What Straumann Is and Why It Matters

Straumann Group is the world's largest dental-implant manufacturer by volume, headquartered in Basel, Switzerland, with research and manufacturing centres across Europe and a global authorised-provider network. The Straumann implant, paired with its SLA and SLActive surface treatments, is the most-cited fixture in the peer-reviewed implantology literature, with documented twenty-plus-year survival data that no other system can match. For a patient who is choosing implants once and wants the most evidence-rich option, Straumann is the default reference against which every other system is benchmarked.

Straumann, Brand and Manufacturer Background

{{IMAGE_PLACEHOLDER:Straumann headquarters or production facility, Basel, Switzerland exterior or clean-room interior}}

The Straumann story starts in 1954 in Waldenburg, Switzerland, initially a precision-machining workshop founded by Reinhard Straumann, focused on alloys for the watchmaking industry. Dental implant work began in 1974 in collaboration with the International Team for Implantology (ITI), led by Professors André Schroeder and Fritz Sutter at the University of Bern. The original ITI/Straumann system pioneered the concept of submerged endosseous titanium implants with rough surfaces, and the partnership with the ITI is unbroken to this day, clinical research and protocol development still flow through the ITI consensus process.

Straumann Group today operates across 100+ markets, with manufacturing concentrated in Switzerland (titanium fixtures), Germany (digital lab equipment), Brazil (the Neodent and Medentika ranges), and the United States. The company acquired Neodent (2012), the Brazilian implant manufacturer focused on the Latin-American market; ClearCorrect (2019), bringing aligner orthodontics under the Straumann umbrella; and several digital-lab and intraoral-scanning brands. Total cumulative implants placed worldwide exceeds 24 million as of the company's most recent annual report.

Regulatory Clearances and Quality Standards

Straumann fixtures hold current clearances across every major regulatory body:

• FDA 510(k), initial clearance 1986; current K-number registry available through the FDA public database
• CE marking, full conformity to EU MDR (2017/745) since the 2024 transition deadline
• TGA Australia, registered medical device (Class IIb)
• CDSCO India, registered through the Bureau of Indian Standards Class C medical device pathway
• MDR EU, full conformity assessment by Notified Body
• PMDA Japan, registered for clinical use

Quality certifications include ISO 13485 medical-device manufacturing across all production sites, ISO 14971 risk management, and full batch traceability via lot numbers etched on every fixture and tracked from manufacturing through patient placement.

Surface Treatment and Osseointegration Profile

The Straumann surface system is the most-studied implant surface in dentistry. Two variants:

SLA (Sandblasted, Large-grit, Acid-etched), the original Straumann surface, introduced 1998. Macro-roughness from large-grit corundum blasting; micro-roughness from hydrochloric and sulfuric acid etching. Sa value of approximately 1.5–2.0 µm. Documented to accelerate osseointegration vs. machined-titanium surfaces, with eight-week unloaded healing as the standard protocol.

SLActive (hydrophilic SLA), introduced 2005. The same SLA mechanical surface, but stored under nitrogen in saline solution to preserve the high surface free energy that titanium normally loses during air exposure. The result: faster bone-to-implant contact in the early healing window, three-to-four-week reduction in time-to-osseointegration, and improved primary stability in low-density bone.

{{IMAGE_PLACEHOLDER:Scanning electron microscope image of SLA or SLActive surface at 1000× magnification}}

The clinical evidence is substantial. Buser et al. (2004) documented 97.0% survival for SLA at five-year follow-up across 511 implants. Roccuzzo et al. (2018) reported 98.8% mandibular SLA survival at twenty-year follow-up, the longest single-system data set in implantology. SLActive in compromised bone (Type IV) shows higher early-stage ISQ values than SLA in the same anatomy (Bornstein 2008, Lang 2011), supporting the immediate-loading protocols that Straumann's Pro Arch and BLX systems are built around.

Surgical Protocol, How Straumann Is Placed

Drill Sequence and Torque Profile

The Straumann surgical protocol uses a brand-specific drill kit with sequential expansion: pilot drill → intermediate drill (or drills, by diameter) → final drill matched to the implant diameter. The standard saline irrigation rate is 50 ml/min per the manufacturer specification. Target insertion torque sits between 35 and 45 Ncm; immediate-load eligibility threshold is 45 Ncm at final seating.

Recommended Primary Stability Threshold

ISQ value at placement of 65 or higher for delayed loading; 70 or higher for immediate loading. The Osstell measurement is taken at placement and verified at the four-week soft-tissue review.

Available Connections

• Bone-Level (Conical Morse-Taper), internal conical connection with platform-switching geometry. The current default for most aesthetic and posterior cases.
• Tissue-Level (Synocta external), the original ITI Straumann connection. Still used in specific anatomical scenarios where soft-tissue biology drives the decision.
• BLX (Tapered), the immediate-loading-optimised connection introduced 2018, designed for high primary stability in fresh extraction sockets and atrophic bone.

Recommended Sites and Indications

Anterior single-tooth (Bone-Level Conical recommended), posterior single-tooth (Bone-Level Conical), multi-unit bridge (Bone-Level Conical or BLX), full-arch (BLX or All-on-X with multi-unit abutments), immediate placement (BLX preferred), immediate load (BLX or SLActive Bone-Level Conical with documented torque/ISQ gate), zygomatic anchor (compatible with Straumann ZAGA and similar protocols).

Prosthetic Options, What Sits On Top

Straumann's prosthetic ecosystem is broad, both Straumann-original components and a wide compatibility with third-party CAD-CAM workflows.

• Cement-retained crowns, abutments at standard or angled correction up to 17°, with platform-switching on Bone-Level Conical
• Screw-retained crowns, for posterior molars and any case where retrievability is preferred
• Multi-unit abutments, straight, 17°, 30° angulation for full-arch protocols
• Locator and ball overdenture attachments, for retentive complete-overdenture cases
• CARES Visual CAD-CAM, Straumann's in-house digital workflow with seamless library compatibility for third-party design software
• Variobase abutments, titanium bases for custom hybrid abutment-crown designs in zirconia and PMMA
• Zirconia abutments, for aesthetic anterior cases where titanium showthrough is a concern

{{IMAGE_PLACEHOLDER:Prosthetic build cross-section showing Straumann Bone-Level Conical implant + abutment + crown stack}}

Indications and Contraindications

Indications

Straumann fixtures are clinically appropriate for: bone density Types I–IV per Misch classification; minimum bone height 8 mm (vertically) and 4 mm (buccolingual width); soft-tissue thickness adequate for prosthetic emergence profile; occlusal forces within physiological range; patient age 18 onwards (skeletal maturity required); systemic health adequate for outpatient surgery; and any single-tooth, multi-unit, or full-arch protocol.

Relative Contraindications

Heavy bruxism (we add a custom occlusal night-guard and consider monolithic zirconia prosthesis); irradiated bone in the implant site within the prior two years; uncontrolled diabetes (HbA1c > 8.0); active periodontal disease at adjacent natural teeth (treat first, then implant); active smoking above ten cigarettes per day (we require thirty-day cessation pre-surgery and document it).

Absolute Contraindications

Active head-and-neck cancer with current radiation therapy; bisphosphonate therapy without a cessation-coordination protocol with the prescribing physician; severe untreated systemic disease that contraindicates surgery; patient unwillingness to commit to the lifetime-maintenance protocol.

What This Costs

Straumann sits at the premium end of the implant-system pricing band. We pay manufacturer-list pricing per fixture and pass it through transparently. The cost differential between Straumann and entry-tier systems (Adin, BioHorizons) is roughly 25–40% per fixture, a meaningful difference at the per-tooth scale, smaller as a proportion of a full-arch case.

EMI options: 0% APR · 12 mo at all major markets via region-specific finance partners (see Cost & Finance hub for partner mapping).

Stunning Dentistry's Experience With Straumann

Straumann has been in our inventory since the founding of Stunning Dentistry in 2008. Across that eighteen-year span we have placed approximately 4,800 fixtures, with named senior surgeons (Dr. Ravi Sharma for surgical, Dr. Kiran Madhav for prosthodontic) supervising the protocol from receipt to discharge. Our 924-implant formal four-year audit (2020–2024) included 612 Straumann fixtures placed across full-arch protocols. Survival in that cohort: 97.2%, in line with the published literature.

We also hold authorised-provider status, Straumann's annual provider audit reviews our placement protocol against the manufacturer-published surgical sequence. The most recent audit (November 2025) issued zero non-conformances.